Relapsed/Refractory Multiple Myeloma: Role and Safety of Bispecific Antibodies
Caitlin Costello, MD, discusses the role and safety of bispecific antibodies approved for the treatment of relapsed/refractory multiple myeloma as well as emerging data and clinical trials with this treatment approach.
Decera Clinical Education Oncology Podcast · Caitlin Costello MD
Audio is streamed directly from the publisher (afp-928689-injected.calisto.simplecastaudio.com) as published in their RSS feed. Play Podcasts does not host this file. Rights-holders can request removal through the copyright & takedown page.
Show Notes
In this episode, Caitlin Costello, MD, discusses important topics related to relapsed/refractory (R/R) multiple myeloma (MM), including:
- 3 bispecific antibodies approved for the treatment of R/R MM that target BCMA or GPRC5D
- The role of bispecific antibodies in R/R MM
- Safety considerations for patients while receiving a bispecific antibody
- Emerging data and clinical trials with bispecific antibodies
- Key clinical pearls for optimal use of bispecific antibodies
Presenter:
Caitlin Costello, MD
Clinical Professor of Medicine
Director, Multiple Myeloma Program
Division of Blood and Marrow Transplantation
Moores Cancer Center
UC San Diego
La Jolla, California
Link to full program:
https://bit.ly/40bjFCZ
Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.